Alkermes, Eli Lilly deal

ALKS and LLY will exclusively develop inhaled formulations of insulin using ALKS's AIR pulmonary drug

Read the full 150 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE